Immunization against cutaneous leishmaniasis (CL) with living, fully virulent parasites has been used in Iran, Israel, and the USSR (8, 11) . This entails inoculating living promastigotes, which leads to normal infection at a selected site on the body and at a suitable time. Microbial contamination, allergic reactions, and the production of chronic disease of many years' duration can occur in addition to lesion formation (6, 19) . The development of effective topical treatment for CL (4) , together with the finding that acquired protection develops before the complete healing of lesions (2, 12, 14) , suggested the combined use of infection and chemotherapy in creating protection.
Leishmania enriettii in guinea pigs is used as a laboratory model of human CL (2, 17, 18, 20) , since lesions usually self-cure and cause protection. A cell-mediated immune response (2, 10) and production of antibody (3, 15) to leishmanial antigen has been demonstrated in infected and convalescent animals. Like CL in humans, the disease in guinea pigs can exhibit a clinical spectrum ranging from simple, self-curing lesions to chronic metastatic disease (2, 5, 13) .
This study in guinea pigs was aimed at determining the effect of topical treatment, given at various times after infection, on the development of protection against CL.
L. enriettii LRC-L327 promastigotes were used to infect and challenge guinea pigs. One or both ears were injected intradermally with 2 x 106 promastigotes. Lesion development was followed by making stained smears and subcultures at different times after infection, as previously described (4). Lesion size was measured (in millimeters) in two diameters (D and d) at right angles to each other, and the lesion size (S; in square millimeters) was determined according to the formula: S = (D x d)l2.
PR ointment containing 15% paromomycin and 12% methylbenzethonium chloride in soft white Paraffin (United Kingdom patent no. GB 2117237 A; analyzed and supplied by Teva Pharmaceutical Industries, Jerusalem) was highly effective against L. enriettii in guinea pigs. After 10 days of treatment, the parasites were eliminated from the treated ears, and the lesions had healed (Fig. 1) . No relapse of the disease was demonstrated in the treated guinea pigs after termination of treatment. In the control group, the parasites generally disappeared spontaneously from the site of infection within 70 to 100 days after infection. When both ears of the guinea pigs were infected and only the right ear was * Corresponding author. treated, a delayed effect was also observed on the untreated lesion of the left ear. These had cured by 30 days after the end of treatment of the right ear (Fig. 2) . However, when a susceptible guinea pig with well-developed lesions and metastases was treated, most of the parasites were eliminated from the treated ear after 10 days of treatment. Twenty days was required to eliminate all of the parasites, and no effect was seen on the parasites in the lesion of the untreated left ear or in the metastatic lesions. Table 1 shows the production of antileishmanial antibodies in infected treated and untreated guinea pigs, as determined by a radioimmunoassay with the supernatant fraction of freeze-thawed and sonicated L. enriettii promastigotes as the coating antigen. Antibody titers did not rise significantly in the infected untreated animals during the first 4 weeks, being 3.5 times higher than that in uninfected untreated controls. This level rose to 6.4 times by 6 weeks and 10.2 times by 8 weeks. Treatment given from 4 weeks onward neither abolished nor reduced antibody production in the treated guinea pigs. Sera from infected treated animals, tested 13 weeks after infection, showed 1.33 to 1.88 times more antibody than did sera from infected, spontaneously cured guinea pigs.
To measure the development of delayed-type hypersensitivity, two types of leishmanin were tested: one made with L. enriettii promastigotes and the other made wtih Leishmania donovani promastigotes made up in 0.5% phenol-saline at 106 promastigotes per ml. Twenty-four hours after intradermal inoculation of leishmanin, slight induration was seen Treated guinea pigs were cured locally of parasites after 10 days of treatment with PR ointment. That a delayed effect was seen on the untreated lesions only in guinea pigs with simple CL, but not in a guinea pig with metastases, suggests that the delayed effect resulted from the development of an immune response rather than through penetration of the drug. A similar phenomenon has also been observed in experimentally infected, treated BALB/c mice (4) and in human CL patients treated locally by cryotherapy (1) .
Antileishmanial vaccine consisting of live virulent promastigotes is the only vaccine presently available. This poses problems, since the process mimics long-term natural infections (6) . The development of an easily applied topical treatment with minimal side effects (4) and the effect described here in guinea pigs suggests that long-term infection during vaccination could probably be shortened from months to weeks. The most accurate way of measuring the development of resistance is to check the ability of hosts to resist challenge infections. Our results indicated that treatment applied 6 weeks, and in most cases even as early as 2 weeks, after infection was not detrimental to the acquisition of protective immunity. The delayed hypersensitivity developed by guinea pigs in this study, although not very strong, developed as early as 4 weeks after infection. Interestingly, the response to L. donovani antigen was slightly higher than that with the homologous L. enriettii antigen.
Although antileishmanial antibodies in humans (20) or guinea pigs (13, 15, 16) do not appear to play a significant role in the development of resistance, they are said to have an important function in healing the primary lesion (5) and can therefore be used to indicate the development of an immune response. The results presented in this study revealed that treatment given at different times starting 4 weeks after infection neither stopped nor abolished antibody production, and their levels remained as high as that in the spontaneously cured, untreated animals at 13 weeks after infection.
The loss of resistance to reinfection after treatment has only been demonstrated in a few cases. Guirges (7) has reported reinfection in 8 out of 3,420 Iraqi patients that had recovered from Leishmania tropica infections. Seven of these eight patients were either under steroid treatment or had been treated chemotherapeutically before their initial lesions healed. In addition, Marzinowsky and Schourenkoff (9) reported experimental reinfection after the surgical removal of active lesions. These examples are too small in number to draw definite conclusions concerning the correlation between treatment and loss of resistance to reinfection. Also, none of the 200 or more patients treated during the last several years at the Hadassah Hospital, including the many living in endemic areas (J. El-On, unpublished data) has become reinfected. This observation, together with the findings presented in this study, suggests that combined infection followed by chemotherapy should be considered in antileishmanial vaccination. Further study must be done in humans to discern the correlation between duration of infection, treatment, and development of protective immunity.
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